Global Breast Cancer Liquid Biopsy

Breast Cancer Liquid Biopsy Comprehensive Study by Type (Circulating Tumor Cells (CTCs), Cell-Free DNA (CfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers), Sample Type (Blood, Serum/ Plasma, Urine, CSF Saliva), End User (Hospitals, Diagnostic Centers, Laboratories) Players and Region - Global Market Outlook to 2030

Breast Cancer Liquid Biopsy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Breast Cancer Liquid Biopsy
Breast cancer remains the leading cause of premature deaths worldwide. Treatment relies on profiling a piece of biopsied tumour tissue. However, the ease of acquiring biopsy depends on patient condition and tumour accessibility. Liquid biopsy has been recently proposed as a promising detection method in oncology that is not only less invasive but also contributes to the early diagnosis of breast cancer. Here, the clinical utility of liquid biopsy as a tool for the early detection of breast cancer. With the introduction of novel techniques, the application of liquid biopsy has been enhanced, enabling the improvement of various aspects of breast cancer management including early diagnosis and screening, prediction of prognosis, early detection of relapse, serial sampling and efficient longitudinal monitoring of disease progress and response to treatment

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Breast Cancer Liquid Biopsy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

QIAGEN N.V. (Netherlands), Roche Diagnostics (United States), Illumina, Inc. (United States), Bio-Rad Laboratories (United States), Myriad Genetics (United States), Menarini Silicon Biosystems (Italy), Cynvenio Biosystems, Inc. (United States), Genomic Health, Inc. (United States), Thermo Fisher Scientific Inc. (United States) and Fluxion Biosciences, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Biodesix, Inc. (United States), Guardant Health, Inc. (United States), Isogen Life Science B.V. (Netherlands) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Breast Cancer Liquid Biopsy market by Type (Circulating Tumor Cells (CTCs), Cell-Free DNA (CfDNA), Extracellular Vesicles (EVs) and Other Circulating Biomarkers) and Region.



On the basis of geography, the market of Breast Cancer Liquid Biopsy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Sample Type, the sub-segment i.e. Blood will boost the Breast Cancer Liquid Biopsy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Breast Cancer Liquid Biopsy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Government Funding & Initiatives

Market Growth Drivers:
Rising implementation of liquid biopsy owing to its advantages over the conventional biopsy expected to boost the liquid biopsy market growth and The rising number of breast cancer cases across the globe

Challenges:
Lack of availability in emerging countries

Restraints:
High cost associated with the breast cancer liquid biopsy

Opportunities:
The rapidly growing demand for non-invasive cancer treatment and the growing prevalence of cancer are the major factors that drive the growth of the Breast Cancer Liquid Biopsy market. and Industry Investments and Initiatives

Market Leaders and their expansionary development strategies
In April 2023, Quest Diagnostics, the nation's leading provider of diagnostic information services, and Haystack Oncology, an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions, today announced a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.
In June 2020 NeoGenomics launched Three Comprehensive Liquid Biopsy Tests Use in Patients With Cancer. The test is for advanced non–small cell lung cancer (NSCLC), all solid tumours, and certain breast cancer tumours, according to a press release.


Key Target Audience
Breast Cancer Liquid Biopsy Providers, Research institutes, Physicians and surgeons, Healthcare service providers and clinical research organizations and Market research and consulting firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Circulating Tumor Cells (CTCs)
  • Cell-Free DNA (CfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers
By Sample Type
  • Blood
  • Serum/ Plasma
  • Urine
  • CSF Saliva

By End User
  • Hospitals
  • Diagnostic Centers
  • Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising implementation of liquid biopsy owing to its advantages over the conventional biopsy expected to boost the liquid biopsy market growth
      • 3.2.2. The rising number of breast cancer cases across the globe
    • 3.3. Market Challenges
      • 3.3.1. Lack of availability in emerging countries
    • 3.4. Market Trends
      • 3.4.1. Government Funding & Initiatives
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Cancer Liquid Biopsy, by Type, Sample Type, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Breast Cancer Liquid Biopsy (Value)
      • 5.2.1. Global Breast Cancer Liquid Biopsy by: Type (Value)
        • 5.2.1.1. Circulating Tumor Cells (CTCs)
        • 5.2.1.2. Cell-Free DNA (CfDNA)
        • 5.2.1.3. Extracellular Vesicles (EVs)
        • 5.2.1.4. Other Circulating Biomarkers
      • 5.2.2. Global Breast Cancer Liquid Biopsy by: Sample Type (Value)
        • 5.2.2.1. Blood
        • 5.2.2.2. Serum/ Plasma
        • 5.2.2.3. Urine
        • 5.2.2.4. CSF Saliva
      • 5.2.3. Global Breast Cancer Liquid Biopsy by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Diagnostic Centers
        • 5.2.3.3. Laboratories
      • 5.2.4. Global Breast Cancer Liquid Biopsy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Breast Cancer Liquid Biopsy (Price)
      • 5.3.1. Global Breast Cancer Liquid Biopsy by: Type (Price)
  • 6. Breast Cancer Liquid Biopsy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. QIAGEN N.V. (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Diagnostics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Illumina, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Myriad Genetics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Menarini Silicon Biosystems (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cynvenio Biosystems, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Genomic Health, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Thermo Fisher Scientific Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Fluxion Biosciences, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Breast Cancer Liquid Biopsy Sale, by Type, Sample Type, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Breast Cancer Liquid Biopsy (Value)
      • 7.2.1. Global Breast Cancer Liquid Biopsy by: Type (Value)
        • 7.2.1.1. Circulating Tumor Cells (CTCs)
        • 7.2.1.2. Cell-Free DNA (CfDNA)
        • 7.2.1.3. Extracellular Vesicles (EVs)
        • 7.2.1.4. Other Circulating Biomarkers
      • 7.2.2. Global Breast Cancer Liquid Biopsy by: Sample Type (Value)
        • 7.2.2.1. Blood
        • 7.2.2.2. Serum/ Plasma
        • 7.2.2.3. Urine
        • 7.2.2.4. CSF Saliva
      • 7.2.3. Global Breast Cancer Liquid Biopsy by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Diagnostic Centers
        • 7.2.3.3. Laboratories
      • 7.2.4. Global Breast Cancer Liquid Biopsy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Breast Cancer Liquid Biopsy (Price)
      • 7.3.1. Global Breast Cancer Liquid Biopsy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Cancer Liquid Biopsy: by Type(USD Million)
  • Table 2. Breast Cancer Liquid Biopsy Circulating Tumor Cells (CTCs) , by Region USD Million (2018-2023)
  • Table 3. Breast Cancer Liquid Biopsy Cell-Free DNA (CfDNA) , by Region USD Million (2018-2023)
  • Table 4. Breast Cancer Liquid Biopsy Extracellular Vesicles (EVs) , by Region USD Million (2018-2023)
  • Table 5. Breast Cancer Liquid Biopsy Other Circulating Biomarkers , by Region USD Million (2018-2023)
  • Table 6. Breast Cancer Liquid Biopsy: by Sample Type(USD Million)
  • Table 7. Breast Cancer Liquid Biopsy Blood , by Region USD Million (2018-2023)
  • Table 8. Breast Cancer Liquid Biopsy Serum/ Plasma , by Region USD Million (2018-2023)
  • Table 9. Breast Cancer Liquid Biopsy Urine , by Region USD Million (2018-2023)
  • Table 10. Breast Cancer Liquid Biopsy CSF Saliva , by Region USD Million (2018-2023)
  • Table 11. Breast Cancer Liquid Biopsy: by End User(USD Million)
  • Table 12. Breast Cancer Liquid Biopsy Hospitals , by Region USD Million (2018-2023)
  • Table 13. Breast Cancer Liquid Biopsy Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 14. Breast Cancer Liquid Biopsy Laboratories , by Region USD Million (2018-2023)
  • Table 15. South America Breast Cancer Liquid Biopsy, by Country USD Million (2018-2023)
  • Table 16. South America Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 17. South America Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 18. South America Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 19. Brazil Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 20. Brazil Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 21. Brazil Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 22. Argentina Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 23. Argentina Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 24. Argentina Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 25. Rest of South America Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 27. Rest of South America Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 28. Asia Pacific Breast Cancer Liquid Biopsy, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 31. Asia Pacific Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 32. China Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 33. China Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 34. China Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 35. Japan Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 36. Japan Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 37. Japan Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 38. India Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 39. India Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 40. India Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 41. South Korea Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 42. South Korea Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 43. South Korea Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 44. Taiwan Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 45. Taiwan Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 46. Taiwan Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 47. Australia Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 48. Australia Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 49. Australia Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 53. Europe Breast Cancer Liquid Biopsy, by Country USD Million (2018-2023)
  • Table 54. Europe Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 55. Europe Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 56. Europe Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 57. Germany Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 58. Germany Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 59. Germany Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 60. France Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 61. France Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 62. France Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 63. Italy Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 64. Italy Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 65. Italy Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 66. United Kingdom Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 67. United Kingdom Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 68. United Kingdom Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 69. Netherlands Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 70. Netherlands Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 71. Netherlands Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 72. Rest of Europe Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 74. Rest of Europe Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 75. MEA Breast Cancer Liquid Biopsy, by Country USD Million (2018-2023)
  • Table 76. MEA Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 77. MEA Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 78. MEA Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 79. Middle East Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 80. Middle East Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 81. Middle East Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 82. Africa Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 83. Africa Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 84. Africa Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 85. North America Breast Cancer Liquid Biopsy, by Country USD Million (2018-2023)
  • Table 86. North America Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 87. North America Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 88. North America Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 89. United States Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 90. United States Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 91. United States Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 92. Canada Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 93. Canada Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 94. Canada Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 95. Mexico Breast Cancer Liquid Biopsy, by Type USD Million (2018-2023)
  • Table 96. Mexico Breast Cancer Liquid Biopsy, by Sample Type USD Million (2018-2023)
  • Table 97. Mexico Breast Cancer Liquid Biopsy, by End User USD Million (2018-2023)
  • Table 98. Breast Cancer Liquid Biopsy: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Breast Cancer Liquid Biopsy: by Type(USD Million)
  • Table 110. Breast Cancer Liquid Biopsy Circulating Tumor Cells (CTCs) , by Region USD Million (2025-2030)
  • Table 111. Breast Cancer Liquid Biopsy Cell-Free DNA (CfDNA) , by Region USD Million (2025-2030)
  • Table 112. Breast Cancer Liquid Biopsy Extracellular Vesicles (EVs) , by Region USD Million (2025-2030)
  • Table 113. Breast Cancer Liquid Biopsy Other Circulating Biomarkers , by Region USD Million (2025-2030)
  • Table 114. Breast Cancer Liquid Biopsy: by Sample Type(USD Million)
  • Table 115. Breast Cancer Liquid Biopsy Blood , by Region USD Million (2025-2030)
  • Table 116. Breast Cancer Liquid Biopsy Serum/ Plasma , by Region USD Million (2025-2030)
  • Table 117. Breast Cancer Liquid Biopsy Urine , by Region USD Million (2025-2030)
  • Table 118. Breast Cancer Liquid Biopsy CSF Saliva , by Region USD Million (2025-2030)
  • Table 119. Breast Cancer Liquid Biopsy: by End User(USD Million)
  • Table 120. Breast Cancer Liquid Biopsy Hospitals , by Region USD Million (2025-2030)
  • Table 121. Breast Cancer Liquid Biopsy Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 122. Breast Cancer Liquid Biopsy Laboratories , by Region USD Million (2025-2030)
  • Table 123. South America Breast Cancer Liquid Biopsy, by Country USD Million (2025-2030)
  • Table 124. South America Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 125. South America Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 126. South America Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 127. Brazil Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 128. Brazil Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 129. Brazil Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 130. Argentina Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 131. Argentina Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 132. Argentina Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 133. Rest of South America Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 134. Rest of South America Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 135. Rest of South America Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 136. Asia Pacific Breast Cancer Liquid Biopsy, by Country USD Million (2025-2030)
  • Table 137. Asia Pacific Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 138. Asia Pacific Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 139. Asia Pacific Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 140. China Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 141. China Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 142. China Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 143. Japan Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 144. Japan Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 145. Japan Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 146. India Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 147. India Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 148. India Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 149. South Korea Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 150. South Korea Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 151. South Korea Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 152. Taiwan Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 153. Taiwan Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 154. Taiwan Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 155. Australia Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 156. Australia Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 157. Australia Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 161. Europe Breast Cancer Liquid Biopsy, by Country USD Million (2025-2030)
  • Table 162. Europe Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 163. Europe Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 164. Europe Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 165. Germany Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 166. Germany Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 167. Germany Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 168. France Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 169. France Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 170. France Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 171. Italy Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 172. Italy Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 173. Italy Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 174. United Kingdom Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 175. United Kingdom Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 176. United Kingdom Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 177. Netherlands Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 178. Netherlands Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 179. Netherlands Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 180. Rest of Europe Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 181. Rest of Europe Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 182. Rest of Europe Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 183. MEA Breast Cancer Liquid Biopsy, by Country USD Million (2025-2030)
  • Table 184. MEA Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 185. MEA Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 186. MEA Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 187. Middle East Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 188. Middle East Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 189. Middle East Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 190. Africa Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 191. Africa Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 192. Africa Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 193. North America Breast Cancer Liquid Biopsy, by Country USD Million (2025-2030)
  • Table 194. North America Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 195. North America Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 196. North America Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 197. United States Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 198. United States Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 199. United States Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 200. Canada Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 201. Canada Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 202. Canada Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 203. Mexico Breast Cancer Liquid Biopsy, by Type USD Million (2025-2030)
  • Table 204. Mexico Breast Cancer Liquid Biopsy, by Sample Type USD Million (2025-2030)
  • Table 205. Mexico Breast Cancer Liquid Biopsy, by End User USD Million (2025-2030)
  • Table 206. Breast Cancer Liquid Biopsy: by Type(USD/Units)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Cancer Liquid Biopsy: by Type USD Million (2018-2023)
  • Figure 5. Global Breast Cancer Liquid Biopsy: by Sample Type USD Million (2018-2023)
  • Figure 6. Global Breast Cancer Liquid Biopsy: by End User USD Million (2018-2023)
  • Figure 7. South America Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 8. Asia Pacific Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 9. Europe Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 10. MEA Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 11. North America Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 12. Global Breast Cancer Liquid Biopsy: by Type USD/Units (2018-2023)
  • Figure 13. Global Breast Cancer Liquid Biopsy share by Players 2023 (%)
  • Figure 14. Global Breast Cancer Liquid Biopsy share by Players (Top 3) 2023(%)
  • Figure 15. Global Breast Cancer Liquid Biopsy share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. QIAGEN N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 18. QIAGEN N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 19. Roche Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Roche Diagnostics (United States) Revenue: by Geography 2023
  • Figure 21. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Illumina, Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 25. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 26. Myriad Genetics (United States) Revenue: by Geography 2023
  • Figure 27. Menarini Silicon Biosystems (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Menarini Silicon Biosystems (Italy) Revenue: by Geography 2023
  • Figure 29. Cynvenio Biosystems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cynvenio Biosystems, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Genomic Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genomic Health, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Fluxion Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Fluxion Biosciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Breast Cancer Liquid Biopsy: by Type USD Million (2025-2030)
  • Figure 38. Global Breast Cancer Liquid Biopsy: by Sample Type USD Million (2025-2030)
  • Figure 39. Global Breast Cancer Liquid Biopsy: by End User USD Million (2025-2030)
  • Figure 40. South America Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 41. Asia Pacific Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 42. Europe Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 43. MEA Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 44. North America Breast Cancer Liquid Biopsy Share (%), by Country
  • Figure 45. Global Breast Cancer Liquid Biopsy: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • QIAGEN N.V. (Netherlands)
  • Roche Diagnostics (United States)
  • Illumina, Inc. (United States)
  • Bio-Rad Laboratories (United States)
  • Myriad Genetics (United States)
  • Menarini Silicon Biosystems (Italy)
  • Cynvenio Biosystems, Inc. (United States)
  • Genomic Health, Inc. (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • Fluxion Biosciences, Inc. (United States)
Additional players considered in the study are as follows:
Biodesix, Inc. (United States) , Guardant Health, Inc. (United States) , Isogen Life Science B.V. (Netherlands) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 231 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Breast Cancer Liquid Biopsy Quantitative research analysis
Global Breast Cancer Liquid Biopsy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as QIAGEN N.V. (Netherlands), Roche Diagnostics (United States), Illumina, Inc. (United States), Bio-Rad Laboratories (United States), Myriad Genetics (United States), Menarini Silicon Biosystems (Italy), Cynvenio Biosystems, Inc. (United States), Genomic Health, Inc. (United States), Thermo Fisher Scientific Inc. (United States) and Fluxion Biosciences, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Government Funding & Initiatives" is seen as one of major influencing trends for Breast Cancer Liquid Biopsy Market during projected period 2023-2030.
The Breast Cancer Liquid Biopsy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Breast Cancer Liquid Biopsy Report?

Have a Query? Click Here

Other Related Reports

Vascular Guidewires Comprehensive Study by Type (Coronary Guidewires, Peripheral Guidewires, Urology Guidewires, Neurovascular Guidewires), Material (Nitinol, Stainless Steel, Other Raw Materials), C...
$ 3450
Pet Dental Care Products Comprehensive Study by Type (Breathe Fresheners & Teeth Cleaning, Dental Supplements, Dental Food & Chews, Others), Distribution Channel (Online Retail, Offline Retail), En...
$ 3650
Juvenile Diabetes Comprehensive Study by Type (Drugs, Delivery Devices), Application (Hospitals, Clinics, Medical Centers), Insulin Analog Type (Rapid-Acting Insulin Analogs, Long-Acting Insulin Anal...
$ 3350
Orthodontics Comprehensive Study by Type (Brackets (Fixed and Removable), Anchorage Appliances (Bands & Buccal Tubes and Miniscrews), Ligatures (Elastomeric Ligatures and Wire Ligatures), Archwires),...
$ 3450
Neuroblastoma Treatment Comprehensive Study by Type (Chemotherapy), Application (Hospitals, Clinics, Others), Treatment Type (Combination Chemotherapy, Monoclonal Antibody Therapy, Vaccine Therapy, O...
$ 3500
Drug Abuse Testing Comprehensive Study by Type (Analyzers, Rapid Testing Devices, Consumables, Laboratory Services), Sample (Urine, Oral Fluid, Breath, Hair, Others), End User (Workplaces & Schools, ...
$ 3450